Dr. Yu on Future Directions in Prostate Cancer
July 25th 2019Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses future directions in prostate cancer.
Read More
Dr. Yu on Initial Findings From the KEYNOTE-365 Trial in mCRPC
July 19th 2019Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses initial findings from the KEYNOTE-365 trial in metastatic castration resistant prostate cancer mCRPC).
Read More
Dr. Yu on Combining Pembrolizumab and Olaparib in mCRPC
June 21st 2019Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combining pembrolizumab and olaparib in metastatic castration-resistant prostate cancer.
Read More
Dr. Yu Discusses Treatment Strategies for Patients With Oligometastatic Prostate Cancer
February 23rd 2019Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment strategies for patients with oligometastatic prostate cancer.
Read More
Dr. Yu on Combination Therapy for Patients With Metastatic Prostate Cancer
February 14th 2019Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination therapy for patients with newly diagnosed metastatic prostate cancer.
Read More
Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer
June 25th 2018Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.
Read More
Dr. Yu on Comorbidities and Therapy Choice in Prostate Cancer
June 6th 2018Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.
Read More
Dr. Yu Discusses Optimal Testosterone Suppression
February 6th 2014Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.
Read More